Jia Hu Baoshi Zhang Fangfang Yao Yan Fu Dianjun Chen Donghui Li Nan Du Analyn Lizaso Jinlei Song Lu Zhang Xiaosong Li
10.1177/1753466620935770
Ther Adv Respir Dis
2020 Jan-Dec;14:1753466620935770.
alk mutations lorlatinib resistance mechanism malignant pleural mesothelioma
CC BY-NC
https://pubmed.ncbi.nlm.nih.gov/32600123/
Anaplastic Lymphoma Kinase / genetics Antineoplastic Agents / therapeutic use Biomarkers, Tumor / genetics Drug Resistance, Neoplasm / genetics Gene Rearrangement Lactams, Macrocyclic / therapeutic use Mesothelioma, Malignant / drug therapy Mutation Oncogene Proteins, Fusion / genetics Pleural Neoplasms / drug therapy Protein Kinase Inhibitors / therapeutic use
Anaplastic Lymphoma Kinase / genetics Antineoplastic Agents / therapeutic use Biomarkers, Tumor / genetics Drug Resistance, Neoplasm / genetics Gene Rearrangement Lactams, Macrocyclic / therapeutic use Mesothelioma, Malignant / drug therapy Mutation Oncogene Proteins, Fusion / genetics Pleural Neoplasms / drug therapy Protein Kinase Inhibitors / therapeutic use Case Reports Adult Aminopyridines Anaplastic Lymphoma Kinase / antagonists & inhibitors Biomarkers, Tumor / antagonists & inhibitors Carbazoles / therapeutic use Humans Lactams Male Mesothelioma, Malignant / enzymology Mesothelioma, Malignant / genetics Mesothelioma, Malignant / pathology Piperidines / therapeutic use Pleural Neoplasms / enzymology Pleural Neoplasms / genetics Pleural Neoplasms / pathology Pyrazoles Treatment Outcome Aminopyridines Antineoplastic Agents Biomarkers, Tumor Carbazoles EML4-ALK fusion protein, human Lactams Lactams, Macrocyclic Oncogene Proteins, Fusion Piperidines Protein Kinase Inhibitors Pyrazoles ALK protein, human Anaplastic Lymphoma Kinase alectinib lorlatinib
PMC7328355
32600123
Acquired multiple mutations ALK I1171N, L1196M and G1202R mediate lorlatinib resistance in EML4-ALK-rearranged malignant pleural mesothelioma: a case report
2020